Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/98066
Title:
Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.
Authors:
Lorigan, Paul C ( 0000-0002-8875-2164 ) ; Lee, Siow Ming; Betticher, Daniel C; Woodhead, M; Weir, D; Hanley, S; Hardy, C; Thatcher, Nick
Abstract:
Although chemotherapy is considered the cornerstone of treatment for small cell lung cancer (SCLC), the majority of SCLC patients relapse and die of their disease within 2 years of diagnosis. Until newer, more effective drugs are developed, both optimization of available chemotherapeutic regimens and the use of combined chemotherapy/radiotherapy will be required to improve the survival of SCLC patients. Combining ifosfamide, carboplatin, and etoposide, among the most active single agents against SCLC, into the ICE regimen was a logical move that has resulted in improved response and survival rates. In limited and extensive SCLC, respectively, ICE and ICE administered with vincristine (VICE) have achieved overall response rates of 79% to 94% and 77% to 100% and 2-year survival rates of 24% to 33% and 9% to 25%, respectively. Treatment-related toxicities, especially myelosuppression, have hindered efforts to accelerate the administration of ICE and VICE regimens and to incorporate them into combined-modality treatments. However, the use of hematologic support measures, including growth factors and peripheral blood progenitor cells, may pave the way for maximizing the effectiveness of these regimens.
Affiliation:
YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
Citation:
Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. 1995, 22 (3 Suppl 7):32-41 Semin. Oncol.
Journal:
Seminars in Oncology
Issue Date:
Jun-1995
URI:
http://hdl.handle.net/10541/98066
PubMed ID:
7610397
Type:
Article
Language:
en
ISSN:
0093-7754
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorLee, Siow Mingen
dc.contributor.authorBetticher, Daniel Cen
dc.contributor.authorWoodhead, Men
dc.contributor.authorWeir, Den
dc.contributor.authorHanley, Sen
dc.contributor.authorHardy, Cen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-05-06T16:15:48Z-
dc.date.available2010-05-06T16:15:48Z-
dc.date.issued1995-06-
dc.identifier.citationChemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. 1995, 22 (3 Suppl 7):32-41 Semin. Oncol.en
dc.identifier.issn0093-7754-
dc.identifier.pmid7610397-
dc.identifier.urihttp://hdl.handle.net/10541/98066-
dc.description.abstractAlthough chemotherapy is considered the cornerstone of treatment for small cell lung cancer (SCLC), the majority of SCLC patients relapse and die of their disease within 2 years of diagnosis. Until newer, more effective drugs are developed, both optimization of available chemotherapeutic regimens and the use of combined chemotherapy/radiotherapy will be required to improve the survival of SCLC patients. Combining ifosfamide, carboplatin, and etoposide, among the most active single agents against SCLC, into the ICE regimen was a logical move that has resulted in improved response and survival rates. In limited and extensive SCLC, respectively, ICE and ICE administered with vincristine (VICE) have achieved overall response rates of 79% to 94% and 77% to 100% and 2-year survival rates of 24% to 33% and 9% to 25%, respectively. Treatment-related toxicities, especially myelosuppression, have hindered efforts to accelerate the administration of ICE and VICE regimens and to incorporate them into combined-modality treatments. However, the use of hematologic support measures, including growth factors and peripheral blood progenitor cells, may pave the way for maximizing the effectiveness of these regimens.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEtoposide-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshVincristine-
dc.titleChemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentYCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.en
dc.identifier.journalSeminars in Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.